亚盛医药-B(06855)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06855 亚盛医药-B

休市中 05-22 16:08:22

41.640

+1.300

+3.22%

最高41.800	最低40.000	成交量233.87万
今开40.340	昨收40.340	日振幅4.46%
总市值155.32亿	流通市值155.32亿	总股本3.73亿
成交额9,619万	换手率0.63%	流通股本3.73亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06855","market":"HK","secType":"STK","nameCN":"亚盛医药-B","latestPrice":41.64,"timestamp":1779437302006,"preClose":40.34,"halted":0,"volume":2338700,"delay":0,"changeRate":0.03222607833415957,"floatShares":373000000,"shares":373000000,"eps":-4.0224465792711115,"marketStatus":"休市中","change":1.3,"latestTime":"05-22 16:08:22","open":40.34,"high":41.8,"low":40,"amount":96194620,"amplitude":0.044621,"askPrice":41.64,"askSize":2200,"bidPrice":41.6,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-4.24834902326456,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779759000000},"marketStatusCode":7,"adr":0,"listingDate":1572192000000,"exchange":"SEHK","adjPreClose":40.34,"openAndCloseTimeList":[[1779413400000,1779422400000],[1779426000000,1779436800000]],"volumeRatio":0.8202281656290672,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06855","defaultTab":"news","newsList":[{"id":"2637363327","title":"亚盛医药-B(06855)：于2026年美国临床肿瘤学会年上公布多项临床进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2637363327","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637363327?lang=zh_cn&edition=full","pubTime":"2026-05-22 07:46","pubTimestamp":1779407170,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B 发布公告，本公司六项入选2026年美国临床肿瘤学会年会的临床研究的摘要已于ASCO官网公布。本届ASCO年会将于2026年5月29日至2026年6月2日在芝加哥伊利诺伊州McCormick会议中心以线上线下结合的形式举办。该方案安全性可控，在儿童相关实体瘤中初步展现抗肿瘤活性，值得进一步研究。主要终点均为24周的主要分子学反应率。研究计划纳入约440例患者，在18个国家126个中心开展，目前正在招募中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444811.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AAPG","BK4139","BK1574","06855","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134177422","title":"异动解读｜亚盛医药盘中上涨7.32%，股东大会释放积极信号叠加指南纳入利好","url":"https://stock-news.laohu8.com/highlight/detail?id=1134177422","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134177422?lang=zh_cn&edition=full","pubTime":"2026-05-21 10:05","pubTimestamp":1779329125,"startTime":"0","endTime":"0","summary":"5月21日，亚盛医药-B盘中上涨7.32%，报41.8港元/股，成交额5379.54万港元。消息面上，公司5月20日召开股东大会，管理层释放多重积极信号：明确核心产品APG-2575将立足自主商业化、不对外出售，已在寻找美国首席商务官；强调与武田的合作\"没有问题\"；并表示MDS适应症为最高优先级临床项目，计划明年下半年申请快速通道资格。此外，公司Bcl-2抑制剂利沙托克拉近日获纳入CSCO两项诊疗指南，在CLL/SLL、AML及MDS领域获权威推荐。多重利好共振推动股价反弹。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636048086","title":"创新药概念走软 药明合联(02268)领跌5.57% 机构成仍看好以创新为主医药科技主线","url":"https://stock-news.laohu8.com/highlight/detail?id=2636048086","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636048086?lang=zh_cn&edition=full","pubTime":"2026-05-18 10:09","pubTimestamp":1779070152,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念整体走软，截至发稿，药明合联 跌5.57%，亚盛医药-B跌5.50%，四环医药跌4.55%，康方生物跌4.49%，歌礼制药-B跌4.36%，同源康医药-B跌4.31%，康诺亚-B跌4.24%，荣昌生物跌4.14%。展望2026年，该机构继续看好以创新为主的医药科技主线，重点关注创新药、脑机接口、AI医疗、手术机器人等，同时建议布局2026年行业有望迎来反转的老龄化及院外消费，关注估值较低的麻药、血制品、中药等。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981521","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","LU0348766576.USD","IE00BPRC5H50.USD","06855","LU0348767384.USD","LU0348827113.USD","159938","LU0417516738.SGD","02410","LU0348825331.USD","159992","02162","IE00B5MMRT66.SGD","LU0348784397.USD","LU2488822045.USD","LU0634319403.HKD","LU2399975544.HKD","BK1583","BK1600","BK1574","09995","BK1593","02268","BK1515","06978","LU2328871848.SGD","LU1794554557.SGD","LU0348735423.USD","01672","09926","LU0348783233.USD","LU2476274308.USD","LU1720050803.USD","IE00B543WZ88.USD","LU1961090484.USD","LU0417516571.SGD","LU1969619763.USD","SG9999014674.SGD","LU2476274720.SGD","BK1161","00460","BK1141","LU0540923850.HKD","09939","LU2778985437.USD","LU0561508036.HKD","LU0417516902.SGD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163156926","title":"亚盛医药-B发布4月股份变动月报表，股本小幅增长10,058股","url":"https://stock-news.laohu8.com/highlight/detail?id=1163156926","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163156926?lang=zh_cn&edition=full","pubTime":"2026-05-07 22:43","pubTimestamp":1778164980,"startTime":"0","endTime":"0","summary":"亚盛医药-B于2026年5月7日发布2026年4月股份变动月报表。公告显示，该公司截至2026年4月30日的法定/注册股本维持500,000,000股普通股，面值每股0.0001美元，对应注册股本共计50,000美元，未产生任何增减变动。公告披露，4月末已发行股份总数为373,334,750股，较3月底增加10,058股，库存股份数量保持为0股。截至4月底，亚盛医药-B股本结构整体保持相对稳定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121412043","title":"亚盛医药-B授予董事股份购回授权，规模达已发行股本10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1121412043","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121412043?lang=zh_cn&edition=full","pubTime":"2026-04-29 06:11","pubTimestamp":1777414276,"startTime":"0","endTime":"0","summary":"亚盛医药-B在最新公告中披露，董事会已向股东大会提呈普通决议案，拟授予董事购回股份的一般授权，最多可回购相当于于批准日已发行股份总数10%的股份。据公告，截至公布前，公司已发行约3.73亿股，所涉回购规模最多约为3733.35万股。股东大会拟于2026年5月20日上午召开，会上将就回购授权进行表决。同时，为确保股东投票权的登记安排，股份过户登记将于2026年5月15日至2026年5月20日期间暂停办理。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"亚盛医药-B授予董事股份购回授权，规模达已发行股本10%","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140767462","title":"亚盛医药-B2025年业绩：收入回落至5.74亿元 研发投入加码致亏损显著扩大","url":"https://stock-news.laohu8.com/highlight/detail?id=1140767462","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140767462?lang=zh_cn&edition=full","pubTime":"2026-04-28 07:19","pubTimestamp":1777331996,"startTime":"0","endTime":"0","summary":"亚盛医药-B在2025年度实现收入5.74亿元人民币，较上年同期的9.81亿元明显下滑，研发投入则从9.47亿元增加至11.37亿元，推动全年亏损大幅上升至12.43亿元。管理层在年报中披露，公司核心业务仍聚焦于创新药物的研发与商业化，尤其是针对肿瘤领域的多条在研管线。公司在收入方面主要来自创新药物相关业务，但与去年相比出现明显回落；毛利约5.25亿元，销售成本上升至约4,894万元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"亚盛医药-B2025年业绩：收入回落至5.74亿元 研发投入加码致亏损显著扩大","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630353293","title":"亚盛医药Bcl-2抑制剂利生妥®获 2026 版 CSCO系列指南多项重磅推荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2630353293","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630353293?lang=zh_cn&edition=full","pubTime":"2026-04-27 09:49","pubTimestamp":1777254540,"startTime":"0","endTime":"0","summary":"利沙托克拉是亚盛医药自主研发的新型口服Bcl-2选择性抑制剂，通过选择性抑制Bcl-2蛋白，恢复癌细胞的正常凋亡过程，从而达到治疗肿瘤的目的。作为中国首个获批上市的国产原创Bcl-2抑制剂，此次利沙托克拉在 2026 版CSCO系列指南中的全面落地，充分展现了该产品在多个血液肿瘤领域的卓越临床价值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4943806_ZH43806_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["IE000M9KFDE8.USD","CSCL","LU1066051811.HKD","LU0203345920.USD","BK4585","SG9999002224.SGD","IE00BSNM7G36.USD","SG9999015945.SGD","LU0234572021.USD","LU0823417653.USD","LU0889566641.SGD","LU1066053197.SGD","SG9999001424.SGD","LU0203347892.USD","LU2237443622.USD","BK1574","LU2247934214.USD","SG9999015986.USD","LU1032955483.USD","IE00BVYPNV92.GBP","LU0348723411.USD","LU0868494708.USD","LU1221951129.SGD","BK4020","LU1162221912.USD","LU0942090050.USD","LU1059921491.USD","LU1066051498.USD","BK4560","LU2237443895.HKD","BK4588","LU1571399168.USD","CSCO","LU1778281490.HKD","CSCS","LU2286300806.USD","AAPG","LU1244550577.SGD","LU1674673691.USD","BK4579","IE00B3PB1722.GBP","LU2102340556.USD","IE00B42XCP33.USD","LU1267930813.SGD","06855","BK4533","BK1161","LU1883839398.USD","LU2237443465.HKD","LU0234570918.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629894566","title":"创新药概念持续拉升 海西新药(02637)领涨12.77%、歌礼制药-B(01672)涨6.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629894566","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629894566?lang=zh_cn&edition=full","pubTime":"2026-04-24 13:11","pubTimestamp":1777007494,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念午后集体持续拉升，截至发稿，海西新药 涨12.77%，歌礼制药-B涨6.27%，诺诚健华涨5.18%，信达生物涨4.10%，科伦博泰生物涨2.84%，亚盛医药-B涨2.79%。西南证券亦表示，医药生物行业近期表现虽相对疲软，估值溢价率有所下降，但行业整体仍保持一定韧性。其他生物制品、医疗研发外包和原料药等细分领域表现突出，显示出医药创新和产业链优势的持续释放。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1979909","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978","HK0000165453.HKD","01477","01672","LU2097828557.USD","06990","01801","09969","LU2242644610.SGD","06855","BK1191","BK1583","LU2097828474.EUR","BK1161","LU2097828714.EUR","LU1969619763.USD","LU0502904849.HKD","LU2097828631.EUR","BK1574","LU2328871848.SGD","LU2488822045.USD","LU0196878994.USD","159992","LU0455707207.USD","LU2097828805.USD","BK1515","BK1589","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629069553","title":"亚盛医药-B(06855)多项研究入选2026 ASCO","url":"https://stock-news.laohu8.com/highlight/detail?id=2629069553","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629069553?lang=zh_cn&edition=full","pubTime":"2026-04-22 07:05","pubTimestamp":1776812706,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B(06855)公布，公司三个重点品种的六项临床研究入选2026年美国临床肿瘤学会(ASCO)年会，其中三项获快速口头报告，三项获壁报展示。这三个重点品种分别为中国首个获批上市的第三代BCR-ABL抑制剂奥雷巴替尼(商品名：耐立克®)、中国首个获批上市的国产塬创Bcl-2选择性抑制剂利沙托克拉(商品名：利生妥®)和MDM2-p53抑制剂Alrizomadlin(APG-115)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431644.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AAPG","06855","BK1161","BK1574","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628721474","title":"亚盛医药-B(06855)授出受限制股份单位及购股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2628721474","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628721474?lang=zh_cn&edition=full","pubTime":"2026-04-20 22:42","pubTimestamp":1776696140,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B 发布公告，截至本公告日期，已向2022年受限制股份单位计划的3名选定人士授出69.63万份受限制股份单位，相当于 69.63万股股份，其中向本公司执行董事兼首席执行官杨大俊博士(杨博士)授出39.38万份受限制股份单位;向本公司首席医学官兼主要股东翟一帆博士(翟博士)授出28.39万份受限制股份单位;及向本公司1名高级管理人员授出1.86万份受限制股份单位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430985.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06855","BK1161","AAPG","BK4139","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628791678","title":"亚盛医药-B(06855)四项临床前进展亮相2026年美国癌症研究协会 (AACR)年会，展现多重联合治疗潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2628791678","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628791678?lang=zh_cn&edition=full","pubTime":"2026-04-20 07:14","pubTimestamp":1776640456,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚盛医药-B 公布，公司将在2026年美国癌症研究协会年会上以壁报形式公布四项临床前研究成果。该会议于2026年4 月17日至2026年4月22日在美国加州圣地亚哥举行。本次壁报涉及公司三个品种，包括：原创1类新药BCR-ABL抑制剂奥雷巴替尼、FAK/ALK/ROS1三联酪氨酸激酶抑制剂APG-2449、以及PRC2/EED抑制剂APG-5918。此外，公司针对BRAF突变肿瘤开展的APG-2449 研究、以及针对小细胞肺癌开展的APG-5918研究，凸显了公司聚焦攻克耐药机制、探索联合用药策略的战略方向。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430403.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AAPG","BK4139","BK1161","06855","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627497821","title":"加速布局儿童实体瘤治疗领域！亚盛医药 MDM2-p53 抑制剂APG-115获CDE纳入\"星光计划\"","url":"https://stock-news.laohu8.com/highlight/detail?id=2627497821","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627497821?lang=zh_cn&edition=full","pubTime":"2026-04-14 12:14","pubTimestamp":1776140040,"startTime":"0","endTime":"0","summary":"此次APG-115获纳入\"星光计划\"，将有助于公司与CDE的进一步紧密沟通，获得儿童人群研究过程中技术问题的针对性指导。APG-115此次获纳入CDE'星光计划'，是国家药监机构对该品种临床价值与研发前景的高度认可。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4933478_ZH33478_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1574","LU1223082519.USD","LU1923622291.USD","BK4017","LU2125909759.SGD","BK4139","LU2125909916.SGD","06855","BK4129","LU1223083913.SGD","APG","CDE","AAPG","LU1223082196.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125511109","title":"亚盛医药-B更新3月股份变动月报表，股本保持平稳","url":"https://stock-news.laohu8.com/highlight/detail?id=1125511109","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125511109?lang=zh_cn&edition=full","pubTime":"2026-04-09 20:06","pubTimestamp":1775736367,"startTime":"0","endTime":"0","summary":"亚盛医药-B于2026年4月9日发布截至2026年3月31日的股份变动月报表。报告显示，公司法定股本与上月保持一致，注册股本仍为500,000,000股普通股，面值每股USD 0.0001，对应法定/注册股本USD 50,000。本报告期内，公司已发行股份由上月底的373,322,192股增至373,324,692股，新增发行2,500股，均来自员工股份期权行使。库存股份数量继续保持为零，无购回或注销活动。期末公司股本总数为373,324,692股，与法定股本相比仍具备充足空间，整体股本结构保持稳定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158877959","title":"异动解读 | 创新药板块多重共振，亚盛医药-B盘中大涨12.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1158877959","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158877959?lang=zh_cn&edition=full","pubTime":"2026-04-01 14:04","pubTimestamp":1775023471,"startTime":"0","endTime":"0","summary":"亚盛医药-B(06855)今日盘中股价大幅上涨12.5%，表现强势。消息面上，今日创新药概念股集体走高，亚盛医药-B作为板块内个股跟随上涨。券商观点指出，2026年中国创新出海趋势持续强化，同时市场对创新药配置有望回升。创新药板块正处于“业绩兑现、估值修复、会议催化”三重周期叠加的黄金窗口期，前期估值风险已得到较为充分的释放。此外，基本面方面，多家药企实现扭亏为盈。即将于4月召开的美国癌症研究协会年会（AACR）等重磅学术会议，也为中国创新药企带来了重要的催化预期，共同推动了板块及个股的上涨行情。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624833564","title":"创新药概念股强势走高 乐普生物-B(02157)涨14.79% 机构指板块迎来多重共振","url":"https://stock-news.laohu8.com/highlight/detail?id=2624833564","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624833564?lang=zh_cn&edition=full","pubTime":"2026-04-01 13:19","pubTimestamp":1775020740,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念股强势走高，乐普生物-B 涨14.79%，荣昌生物涨14.41%，欧康维视生物-B涨14.25%，亚盛医药-B涨12.07%，博安生物涨11.41%，诺诚健华涨11.21%，海西新药涨11.19%，三生制药涨10.78%，康诺亚-B涨10.21%。华鑫证券表示，2026年中国创新出海趋势持续强化，同时市场对创新药配置有望回升，维持医药行业“推荐”的评级。创新药迎来重要配置机遇，看好目前处于领先位置的双抗和多抗组合。期待今年年4-6月重磅学术会议带来的中国创新药企重磅研究。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1978033","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162","BK1593","01477","HK0000165453.HKD","09969","LU1969619763.USD","06955","06978","BK1161","159992","02157","09995","BK1587","BK1574","BK1583","LU2328871848.SGD","02637","06855","BK1191","01530"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622811719","title":"“十亿美元分子”双核共振，亚盛医药-B(06855)加速全球创新价值兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=2622811719","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622811719?lang=zh_cn&edition=full","pubTime":"2026-03-27 11:49","pubTimestamp":1774583348,"startTime":"0","endTime":"0","summary":"3月26日，亚盛医药-B2025年年度业绩正式出炉。“十亿美元分子”双核共振，夯实创新与全球化根基作为一家已经进入商业化加速阶段的创新药企业，亚盛医药在2025年最核心的价值研判锚点在于：不同于此前依靠耐立克“单点突破”，公司现阶段的全球商业化已步入“十亿美元分子”双核共振关键期。作为亚盛医药的第二款商业化产品，利生妥报告期内获批上市，为公司“十亿美元分子”双核共振奠定了重要基础，也成为公司业绩加速增长的关键一极。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420256.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","AAPG","BK1161","06855","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151997129","title":"异动解读 | 获券商看好业绩与管线，亚盛医药-B盘中大涨7.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=1151997129","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151997129?lang=zh_cn&edition=full","pubTime":"2026-03-27 11:32","pubTimestamp":1774582361,"startTime":"0","endTime":"0","summary":"亚盛医药-B(06855)今日盘中股价大幅上涨7.95%，引起了市场关注。消息面上，中信建投证券发布研究报告，维持对亚盛医药的“买入”评级。报告指出，公司2025年业绩符合预期，核心产品奥雷巴替尼营收实现大幅增长，另一产品利沙托克拉商业化前景优异。同时，公司多个全球三期临床试验持续推进，构成了未来的增长动力，增强了投资者对公司发展潜力的信心。财务数据显示，公司2025年产品销售收入同比增长90%，账上现金充足。券商报告预计公司未来几年收入将持续增长。这些积极因素共同推动了今日股价的显著上扬。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622811531","title":"【券商聚焦】中信建投证券维持亚盛医药(06855)“买入”评级 基于商业化产品放量及国际化管线潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2622811531","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622811531?lang=zh_cn&edition=full","pubTime":"2026-03-27 11:17","pubTimestamp":1774581463,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券发布研报指，亚盛医药 2025年业绩符合预期，核心投资论点基于其商业化产品放量及国际化管线潜力。报告认为，公司核心产品奥雷巴替尼营收实现大幅增长，利沙托克拉商业化前景优异，且两款产品的多个全球三期临床持续推动，构成未来增长动力。另一产品利沙托克拉在上市后五个月实现销售收入7058万元。基于商业化放量及管线潜力，维持对亚盛医药-B的“买入”评级。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977474","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AAPG","06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622788916","title":"亚盛医药-B(06855)2025年股东亏损同比扩大206.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622788916","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622788916?lang=zh_cn&edition=full","pubTime":"2026-03-26 08:46","pubTimestamp":1774485965,"startTime":"0","endTime":"0","summary":"金吾财讯 | 亚盛医药-B(06855)公告公布，截至2025年12月31日止年度，母公司拥有人应占亏损12.43亿元(人民币，下同)，同比亏损扩大206.53%；每股基本亏损3.49元。期内，集团收入5.74亿元，同比减少41.46%。耐立克（奥雷巴替尼）销售额同比增长81%至4.35亿元。期内，集团研发开支11.37亿元，同比增长20.08%。","market":"nz","thumbnail":"https://static.szfiu.com/news/20200915/NjdlOTQyZDE5NzA3MzU4ZTU3YTk2ZGQ0MjAwMDE4NjcyODIz.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200915/NjdlOTQyZDE5NzA3MzU4ZTU3YTk2ZGQ0MjAwMDE4NjcyODIz.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977283","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK4139","AAPG","BK1574","06855"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622588314","title":"亚盛医药-B(06855)双引擎驱动高增长，耐立克销售同比大增81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622588314","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622588314?lang=zh_cn&edition=full","pubTime":"2026-03-26 07:28","pubTimestamp":1774481290,"startTime":"0","endTime":"0","summary":"3月26日，头部创新药企业亚盛医药发布2025年全年业绩。作为公司首款商业化产品，耐立克在2025年迎来医保落地后的首个完整销售年份，销售额实现显著增长，达到4.35亿元人民币，同比大幅增长81%。公司第二款产品、中国首个上市的国产原创Bcl-2抑制剂利生妥自2025年7月获批后快速放量，截至报告期末的5个月内实现销售额7058万元人民币。业绩增长由已上市的两大核心产品“双引擎”高效驱动。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419181.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"亚盛医药-B(06855)双引擎驱动高增长，耐立克销售同比大增81%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","AAPG","06855","BK1574","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascentagepharma.com","stockEarnings":[{"period":"1week","weight":0.0595},{"period":"1month","weight":-0.1635},{"period":"3month","weight":-0.1226},{"period":"6month","weight":-0.3117},{"period":"1year","weight":-0.1458},{"period":"ytd","weight":-0.2031}],"compareEarnings":[{"period":"1week","weight":-0.0137},{"period":"1month","weight":-0.0213},{"period":"3month","weight":-0.0306},{"period":"6month","weight":0.0153},{"period":"1year","weight":0.0876},{"period":"ytd","weight":-0.001}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"亚盛医药集团是一家主要从事血液系统恶性肿瘤疗法的发现、开发和商业化的投资控股公司。该公司的主要产品包括耐立克（奥雷巴替尼）、Lisaftoclax（APG-2575）、Alrizomadlin（APG-115）、Pelcitoclax（APG-1252）、APG-5918、以及APG-2449。该公司的产品主要用于治疗慢性髓性白血病（CML）、急性髓性白血病（AML）、慢性淋巴细胞白血病（CLL）、急性淋巴细胞白血病（ALL）、骨髓增生异常综合征（MDS）以及多发性骨髓瘤（MM）。该公司主要在国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.285714,"avgChangeRate":-0.091562},{"month":2,"riseRate":0.285714,"avgChangeRate":-0.033966},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.093205},{"month":4,"riseRate":0.714286,"avgChangeRate":0.098263},{"month":5,"riseRate":0.428571,"avgChangeRate":0.037086},{"month":6,"riseRate":0.833333,"avgChangeRate":0.306068},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.077026},{"month":8,"riseRate":0.833333,"avgChangeRate":0.051008},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.083178},{"month":10,"riseRate":0.5,"avgChangeRate":0.039816},{"month":11,"riseRate":0.428571,"avgChangeRate":0.061723},{"month":12,"riseRate":0.571429,"avgChangeRate":0.04635}],"exchange":"SEHK","name":"亚盛医药-B","nameEN":"ASCENTAGE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亚盛医药-B(06855)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亚盛医药-B(06855)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亚盛医药-B,06855,亚盛医药-B股票,亚盛医药-B股票老虎,亚盛医药-B股票老虎国际,亚盛医药-B行情,亚盛医药-B股票行情,亚盛医药-B股价,亚盛医药-B股市,亚盛医药-B股票价格,亚盛医药-B股票交易,亚盛医药-B股票购买,亚盛医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亚盛医药-B(06855)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亚盛医药-B(06855)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}